Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

To laugh or cry after reading about neratinib in the following article? It discusses Puma Biotechnology neratinib’s chances at the scheduled Oncologic Drugs Advisory Committee meeting for May 24. As you know, Poziotinib may compete in the same space as neratinib.

Per the article “Adam Feuerstein, writing for The Street, notes that the committee’s Rick Pazdur has only scheduled five hours for the meeting, which he feels is bad news for Puma—although he also notes opposing opinions on the matter…. Feuerstein writes, “If FDA history is a guide, an abbreviated turn in front of a panel of outside experts spells a bad outcome for Puma. Over the past five years, Pazdur has often used half-day sessions of the FDA Oncologic Drugs Advisory Committee (ODAC) to administer public floggings to flawed cancer drugs.”

I don’t know what to think of this except to leave it to AF to come up with this thought.

http://www.biospace.com/News/fdas-shorten-review-time-is-a-bad-sign-for-puma/453001?type=email&source=GP_041917